Biomerieux, Inc.

National Institute of Health and Medical Research

National Institute for Agricultural Research

Francois Mallet

Bernard F Mandrand

Herve Perron

Frederic Bedin

Frederic Beseme

Philippe L Cleuziat

Pierre Levasseur

Francoise Guillou-Bonnici

Glaucia Paranhos-Baccala

Guy Oriol

Francois-Loic Cosset

Florence Komurian-Pradel

Maud Arsac

Mireille Sodoyer

Catherine Ott

Bertrand Bonnaud

Jean-Philippe Pichon

Thierry Delair

Marie-Helene Charles

Jacques Samarut

Armelle Novelli-Rousseau

Didier Poncet

Miloud Benchaibi

Dimitri Lavillette

Pierre Savatier

Gerard Verdier

Pierrick Thoraval

Victor-Marc Nigon

Catherine Legras

Yahia Chebloune

Astrid Reyss-Brion

Mustapha Belakebi

Valerie Cheynet

Cecile Voisset

Claude Bagnis

Jean-Luc Blond

Olivier Bouton

Alessia Ruggieri

Catherine Ladaviere

Juliette Gimenez

Cecile Montgiraud

The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker.

Method for in vitro diagnosis or prognosis of testicular cancer

A peptide domain necessary for an interaction between an envelope of a virus belonging to an HERV-W interference group and an hASCT receptor comprises (i) an N-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 1 to SEQ ID No. 29, (ii) a C-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 30 to SEQ ID No. 40, and (iii) at least one motif between the N-terminus and the C-terminus, and having an amino acid sequence selected from the group consisting of: SEQ ID No. 41, SEQ ID No. 42 and SEQ ID No. 73.

Methods for producing peptides including HERV-W envelope motifs and for producing antibodies specific for the peptides

A method for in vitro diagnosis or prognosis of testicular cancer in a biological sample from a patient suspected of suffering from testicular cancer, having a step of detecting the presence or absence of methylation of CpG dinucleotides in at least one genomic DNA target sequence of the sample, the target sequence being selected from at least one of the sequences identified in SEQ ID NOS: 1 to 7 or from at least one sequence which exhibits at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 7 and the sequences complementary thereto; to the DNA sequences and to the use thereof as a testicular cancer marker.

Method for the in vitro diagnosis or prognosis of testicular cancer

An isolated polynucleotide having a nucleotide sequence selected from the group consisting of (a) SEQ ID NO: 21, (b) the full-length sequences encoding a polypeptide having a peptide sequence selected from the group consisting of SEQ ID NOs: 25 and 26, and (c) the full-length complementary sequences to the sequences set forth in (a) or (b).

Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region

The invention concerns a nucleic material, in isolated or purified state, and a nucleotide fragment comprising a nucleotide sequence selected from the group consisting in (i) the sequences SEQ ID NO: 112, SEQ ID NO:114, SEQ ID NO: 117, SEQ ID NO: 120, SEQ ID NO. 124, SEQ ID NO: 130, SEQ ID NO: 141 and SEQ ID NO: 142, (ii) the complementary sequences of sequences (i); and (iii) the sequences equivalent to sequences (ii) and (iii), in particular the sequence having for every series of 100 contiguous monomers, at least 50%, preferably 70% homology with sequences (i) and (ii) respectively. The invention also concerns their uses for detecting a retrovirus associated with multiple sclerosis and/or rheumatoid arthritis.

Multiple sclerosis-associated retroviral (MSRV) nucleic acids corresponding to the Env region

The invention concerns an endogenic nucleic fragment, such as an isolated retrovirus, integrated in the human DNA genome, the fragment being characterized in that it comprises, or consists of, at least part of the gag gene of an endogenetic retrovirus associated with an autoimmune disease or pregnancy failure or pregnancy pathologies, said part at least coding, directly and indirectly, for an expression product, or the complement of the fragment.

Endogeneous nucleic acid fragment associated with an autoimmune disease, labeling method and reagent

A method for detecting the expression of a polypeptide in cells and for detecting the interaction between a polypeptide and cells, ex vivo or in vitro, wherein the polypeptide is selected from the group consisting of: a peptide comprising the cyt domain of the envelope protein of the human endogenous retrovirus, HERV-W; a peptide comprising amino acids 448-538 of SEQ ID NO: 1; and a peptide comprising a sequence having, for any series of 20 amino acids, at least 80% identity with amino acids 448-538 of SEQ ID NO: 1. Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation.

Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein

An RNA amplification method is particularly useful for diagnosing bacterial or viral infections or genetic disorders and for cell typing. The method includes the steps of denaturing a solution containing RNA, synthesizing a first cDNA strand from a suitable primer in the presence of reverse transcriptase, denaturing the heteroduplex formed, synthesizing a second cDNA strand from a second primer in the presence of DNA polymerase and then subjecting the cDNA formed to a sufficient number of amplification cycles. All the reactants and solvents are first placed in the same container to provide a single manipulation step that avoids the risk of contamination.

RNA amplification method requiring only one manipulation step

The invention concerns a method for isolating a target biological material contained in a sample, which consists in providing a capture phase comprising an organic molecule having at least a reactive function and at least a protein material capable of recognizing or binding, specifically and directly or indirectly, with the target biological material, said protein material having a specific covalent binding site with the organic molecule reactive function, consisting of at least a tag comprising at least six contiguous lysine, or lysine derivative residues, the method consists in contacting said target biological material with at least the capture phase; and detecting the target biological material fixed on the capture phase: The invention also concerns the capture and detection phases, and a reagent containing them.

Method for isolating a target biological material, capture phase, detecting phase and reagent containing them

Composition comprising two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of said virus, and a second agent, or a variant of said second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8 1993 under Accession Number V93010816, and from their variant strains.

Cell lines and viral isolates associated with multiple sclerosis

The extension of primers capable of hybridizing to the nucleic acid of interest results in a process for generating single-stranded polynucleotides. The process includes contacting the nucleic acid of interest under conditions allowing extension of the primers with a first primer and a second primer capable of hybridizing to a first region and a second region, respectively, of the nucleic acid, wherein the second region overlaps with the first region.

Method for nucleic acid amplification by transcription using displacement, and reagents and kit therefor

Composition comprising two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of said virus, and a second agent, or a variant of said second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22, 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8, 1993 under Accession Number V93010816, and from their variant strains.

Viral isolates associated with multiple sclerosis

Composition including two pathogenic and/or infective agents associated with multiple sclerosis, namely a first agent which consists of a human virus possessing reverse transcriptase activity and related to a family of endogenous retroviral elements, or a variant of the virus, and a second agent, or a variant of the second agent, these two pathogenic and/or infective agents originating from the same viral strain chosen from the strains designated, respectively, POL-2 deposited with the ECACC on Jul. 22, 1992 under Accession Number V92072202 and MS7PG deposited with the ECACC on Jan. 8, 1993 under Accession Number V93010816, and from their variant strains.

MSRV1 virus and MSRV2 pathogen and/or infective agent associated with

An oligonucleotide is intended to be used as a promoter non-template strand in the transcription of a sequence of a nucleotide target in the presence of a phage RNA polymerase. The phage RNA polymerase has specific natural promoters containing a consensus sequence from at least position -17 to position -1. The oligonucleotide contains a core sequence flanked at at least one of its ends by a nucleotide sequence capable of hybridization with a sequence of the target. The core sequence contains a sequence of 6 to 9 consecutive nucleotides from the region -12 to -4 of the non-template strand of the specific promoter, or a sufficiently homologous sequence to enable the functionality of the RNA polymerase to be retained. One flanking sequence is complementary to a first region of the target, and a second flanking sequence, when present, is complementary to a second region of the target, the first and second regions being separated on the target by a sequence having a number of nucleotides equal to the number of nucleotides in the core sequence. The number of nucleotides in the flanking region, or the sum of the number of nucleotides in the flanking regions, is at least sufficiently high for the nucleotide to be able to hybridize with the target at the temperature of use of the RNA polymerase. Such an oligonucleotide enables transcription to be initiated at a site of the target which is not normally a transcription start site for the RNA polymerase.

Modified promoter for RNA polymerase, its preparation and its

Growing community of inventors

Villeurbanne, France

Francois Mallet